Es­pe­ri­on strikes Japan deal for 'goldilock­s' cho­les­terol drug, bags $60M cash as pan­dem­ic forces vir­tu­al US roll­out

Es­pe­ri­on has forged its first re­gion­al deal for Nexle­tol and Nexl­izet since win­ning US and EU ap­provals for the cho­les­terol fight­ing drugs, bag­ging $60 mil­lion up­front while se­cur­ing a phar­ma part­ner in Japan.

Not on­ly is Ot­su­ka promis­ing $450 mil­lion in to­tal mile­stones and 15% to 30% roy­al­ties, it’s al­so pick­ing up the tab for all de­vel­op­ment, reg­u­la­to­ry and sales in Japan — which Es­pe­ri­on es­ti­mates would amount to $100 mil­lion over the next few years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.